Donnerstag, 2. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
MIROVA

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Rekrutierend

NCT-Nummer:
NCT04274426

Studienbeginn:
Oktober 2021

Letztes Update:
16.01.2024

Wirkstoff:
Carboplatin, Pegylated Liposomal Doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine

Indikation (Clinical Trials):
Recurrence

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
AGO Research GmbH

Collaborator:
-

Studienleiter

Philipp Harter
Study Chair
Kliniken Essen-Mitte, Germany

Kontakt

Studienlocations
(3 von 19)

Städtische Klinikum Dessau
Dessau
(Sachsen-Anhalt)
GermanyRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

136 patients will be randomized into the follow-ing two treatment arms as specified below:

Arm A: Control arm Platinum-based chemotherapy Arm B: Carboplatin + Mirvetuximab soravtansine

(IMGN853)

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. All patients must have a pathologically documented, definite diagnosis of epithelial

cancer of the ovary, the fallopian tube or the peritoneum

2. Relapsed disease with a platinum-free interval >3 months

3. All histologic subtypes of ovarian carcinoma including carcinosarcoma (malignant mixed

Mullerian tumors, MMMT)

4. Patients with wildtype BRCA1/2 mutation status or with a deleterious BRCA1/2 mutation

in germline or somatic testing if they underwent PARP inhibitor therapy in previous

treatment line.

5. Patients must be willing to provide archival tumor tissue from current relapse or

previous surgeries/biopsies for central confirmation of FRα high status by PS2+

scoring:

all tumors must exhibit ≥75% of tumor cells with FRα membrane staining and ≥ 2+

intensity by immunohistochemistry (IHC) using the Ventana FOLR1 (FOLR1 2.1) CDx assay.

6. Patients must have measurable disease or evaluable disease in combination with GCIG

CA-125 criteria.

7. Patients had one or more prior lines of chemotherapy. The last line of chemotherapy

should have included platinum and has resulted in a partial or complete response.

8. Major surgery (not including placement of vascular access device, tumor punch/scrape

biopsies or secondary wound closure) must be completed four weeks prior to Day 1.

9. Patients must have adequate hematological, liver, cardiac and kidney function:

1. Hemoglobin ≥ 10.0 g/dL.

2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

3. Platelet count ≥ 100 x 109/L.

4. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).

5. Aspartate aminotransferase/Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT))

and Alanine aminotransferase/Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤

2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x

ULN.

6. Serum creatinine ≤ 1.5 x institutional ULN and glomerular filtration rate of at

least 40 ml/minute according to Cockroft-Gault formula.

10. Patient is female and ≥18 years of age at the time of the first screening visit.

11. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

12. Patients must be willing and able to sign the informed consent form, and to adhere to

the study visit schedule and other protocol requirements.

13. Women of childbearing potential (a woman is considered of childbearing potential

(WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless

permanently ster-ile. Permanent sterilization methods include hysterectomy, bi-lateral

salpingectomy and bilateral oophorectomy) must have a negative serum pregnancy test

within 3 days from day 1 of cycle 1 and agree to use a highly effective method of

contraception while on study treatment and for at least 6 months after end of

treatment. Such methods include:

1. Combined (estrogen and progestogen containing) hor-monal contraception associated

with inhibition of ovulation:

- oral

- intravaginal

- transdermal

2. Progestogen-only hormonal contraception associated with inhibition of ovulation:

- oral

- injectable

- implantable

3. Intrauterine device (IUD)

4. Intrauterine hormone-releasing system ( IUS)

5. Bilateral tubal occlusion

6. Vasectomized partner

7. Sexual abstinence

Exclusion Criteria:

1. Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (i.e.

germ cell tumors)

2. Ovarian tumors of low malignant potential (e.g. borderline tumors).

3. Unknown BRCA status.

4. Patients who are planned to receive bevacizumab for the current relapse.

5. Other malignancy within the last 3 years (except cervix or breast in situ carcinoma,

type I stage I endometrial cancer)

6. Patients who underwent surgery for the current relapse with macroscopic complete

resection

7. Prior systemic anticancer therapy within 28 days before randomization

8. Prior treatment with folate receptor-targeting investigational agents is not allowed.

9. Patients with > Grade 1 peripheral neuropathy.

10. Serious concurrent illness or clinically-relevant active infection

11. Previous clinical diagnosis of non-infectious interstitial lung disease, including

non-infectious pneumonitis.

12. Active or chronic corneal disorders such as Sjogren's syndrome, Fuchs corneal

dystrophy (requiring treatment), history of corneal transplantation, active herpetic

keratitis, active ocular conditions requiring ongoing treatment/monitoring such as

uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal

injections, active diabetic retinopathy with macular edema, macular degeneration,

presence of papilledema, and /or monocular vision. Active or chronic corneal disorder

13. Required use of folate-containing supplements (e.g. folate deficiency)

14. Women of childbearing potential (WOCBP) not protected by highly effective

contraceptive methods.

15. Pregnant and/or breast-feeding women.

16. Known hypersensitivity to one of the chemotherapy re-gimes and/or PARP inhibitors

and/or any of their excipients.

17. Patients with prior hypersensitivity to monoclonal antibodies.

18. Patients with potential risks according to contraindication, warnings or interactions

of the used chemotherapeutic agents as stated in the SmPCs are not eligible for

partici-pation in this trial.

19. Patients with untreated or symptomatic central nervous system (CNS) metastases

Studien-Rationale

Primary outcome:

1. Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assess-ment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). (Time Frame - Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier.):
PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).



Secondary outcome:

1. OS (Time Frame - Up to 2.5 years. From date of randomization until date of death from any cause.):
Overall survival

2. ORR (Time Frame - Up to 2.5 years. From date of randomization to date of death death from any cause.):
Objective response rate

3. Efficacy regarding PFS (Time Frame - Up to 2.5 years. From date of randomization to date of death from any cause.):
Efficacy regarding Progression Free Survival depending on histologic subtype

4. Efficacy regarding OS (Time Frame - Up to 2.5 years. From date of randomization to date of death from any cause.):
Efficacy regarding Overall Survival depending on histologic subtype

5. Efficacy regarding ORR (Time Frame - Up to 2.5 years. From date of randomization to date of death from any cause.):
Efficacy regarding Objective Response Rate depending on histologic subtype

6. Serological progressive disease (Time Frame - Up to 2.5 years. From date of randomization to date of death death from any cause.):
Time to serological progressive disease according to GCIG criteria

7. Time to first subsequent treatment (TFST) (Time Frame - Up to 2.5 years. From date of randomization to date of death from any cause.):
Time to first subsequent treatment (TFST)

8. Time to second subsequent treatment (TSST) (Time Frame - Up to 2.5 years. From date of randomization until date of death from any cause.):
Time to second subsequent treatment (TSST)

9. Patient-reported outcomes (Time Frame - Up to 2.5 years. From date of randomization until date of death from any cause.):
Quality of Life (EORTC C-30)

10. Patient-reported outcomes (Time Frame - Up to 2.5 years. From date of randomization until date of death from any cause.):
Quality of Life (EORTC OV28)

11. Safety and tolerability (Time Frame - Up to 2.5 years. From date of randomization until date of death from any cause through study completion.):
Safety and tolerability of the used drugs evaluated by NCI CTCAE v5.0

Studien-Arme

  • Active Comparator: Control arm with Platinum-based chemotherapy
    Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 & d8) q21d Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d
  • Experimental: Carboplatin + Mirvetuximab soravtansine (IMGN853)
    Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.

Geprüfte Regime

  • Carboplatin:
    Carboplatin will administered by intravenous route
  • Pegylated liposomal doxorubicin (PLD):
    PLD will be administered by intravenous route
  • Gemcitabine:
    Gemcitabine will be administered by intravenous route
  • Paclitaxel:
    Paclitaxel will be administered by intravenous route
  • Mirvetuximab Soravtansine:
    Mirvetuximab Soravtansine will be administered by intravenous route

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.